Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2023-05-01
2023-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Metal Panel Allergen Patch Test Study
NCT04500834
Cutaneous and Systemic Reactions to Metal Implants
NCT02483728
Skin Irritation Test of Ten Products
NCT05245383
Detection of Aluminium-reactive T-lymphocytes in Patients With Vaccination Granulomas
NCT06130462
Induction of Suction Blisters in Patients With Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neoplastic Disorders, and in Normal Volunteers
NCT00001150
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Day 15: Receive 2nd intradermal injection of 0.1 mL atelocollagen skin test into right volar forearm (14 days after 1st injection).
Day 45: Final assessment of both injection sites (30 days after 2nd injection)
Note: ALL injection sites will be assessed clinically at 30 minutes (for observational purposes) and at 72 hours (to determine response) after each injection. Visit windows for 72 hour assessments, and Day 15 and Day 45 visits can occur up to 96 hours (4 days) after target time.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bovine Atelocollagen Skin Sensitization Test
Volunteer cohort tested for hypersensitivity towards intradermal injection of bovine atelocollagen.
Bovine atelocollagen intradermal injection
Intradermal skin test injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bovine atelocollagen intradermal injection
Intradermal skin test injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Volunteers must be capable of understanding and following directions in English.
* Subjects who are healthy and have normal skin on the volar surface of the forearm.
* Subjects willing and able to comply with the requirements of the study.
* Subjects willing and able to comply with the follow-up requirements.
* Subjects willing and able to give written and verbal informed consent.
Exclusion Criteria
* Current treatment by a physician for allergy, unless physician consulted by Investigator and participation was approved.
* Participation in a repeat insult patch test (RIPT), skin prick test (SPT) or follow-up work within the last month.
* Recent immunization, including COVID-19 (less than 14 days prior to skin test).
* Subjects who have had any form of collagen soft tissue treatment within the last 12 months.
* Subjects with medical history indicating atopy or dermatographia ('skin writing').
* Subject has a current skin disease of any type apart from mild facial acne (e.g., eczema, psoriasis).
* Subject has any skin pathology or condition that could interfere with the evaluation of the treatment areas.
* Subjects who were or are currently being treated with any systemic immuno-suppressive therapy, including but not limited to chemotherapy agents or cortico-steroids (including inhaled or insufflated) within the past 3 months.
* Subjects who were or are currently being treated with any topical OTC drug or prescription therapy on their arms (below the elbow) within the past 3 months.
* Subjects with a history indicative of abnormal immune function (e.g., auto- immune diseases, HIV, cancer, etc.).
* Subjects with known lidocaine hypersensitivity.
* Subjects with known sensitivity to bovine collagen.
* Subjects who have a history of dietary beef allergy, undergoing desensitization to beef products or planning to undergo desensitization within the study evaluation period.
* Subjects with severe allergies manifested by a history of anaphylaxis.
* Subject is currently enrolled in an investigational drug or device study.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AscentX Medical, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Rullan, MD
Role: PRINCIPAL_INVESTIGATOR
Dermatology Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dermatology Institute
Chula Vista, California, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Cooperman LS, Mackinnon V, Bechler G, Pharriss BB. Injectable collagen: a six-year clinical investigation. Aesthetic Plast Surg. 1985;9(2):145-51. doi: 10.1007/BF01570347.
Lynn AK, Yannas IV, Bonfield W. Antigenicity and immunogenicity of collagen. J Biomed Mater Res B Appl Biomater. 2004 Nov 15;71(2):343-54. doi: 10.1002/jbm.b.30096.
Velosa APP, Brito L, de Jesus Queiroz ZA, Carrasco S, Tomaz de Miranda J, Farhat C, Goldenstein-Schainberg C, Parra ER, de Andrade DCO, Silva PL, Capelozzi VL, Teodoro WR. Identification of Autoimmunity to Peptides of Collagen V alpha1 Chain as Newly Biomarkers of Early Stage of Systemic Sclerosis. Front Immunol. 2021 Feb 12;11:604602. doi: 10.3389/fimmu.2020.604602. eCollection 2020.
Pendaries V, Gasc G, Titeux M, Leroux C, Vitezica ZG, Mejia JE, Decha A, Loiseau P, Bodemer C, Prost-Squarcioni C, Hovnanian A. Immune reactivity to type VII collagen: implications for gene therapy of recessive dystrophic epidermolysis bullosa. Gene Ther. 2010 Jul;17(7):930-7. doi: 10.1038/gt.2010.36. Epub 2010 Apr 8.
Ujiie H, Yoshimoto N, Natsuga K, Muramatsu K, Iwata H, Nishie W, Shimizu H. Immune Reaction to Type XVII Collagen Induces Intramolecular and Intermolecular Epitope Spreading in Experimental Bullous Pemphigoid Models. Front Immunol. 2019 Jun 19;10:1410. doi: 10.3389/fimmu.2019.01410. eCollection 2019.
Daniels, et al. Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution. US 3,949,073, United States Patent and Trademark Office, 6 April 1976.
Luck, et al. Aqueous collagen composition. US 4,140,537, United States Patent and Trademark Office, 20 February 1979.
Luck, et al. Non-antigenic collagen and articles of manufacture. US 4,233,360, United States Patent and Trademark Office, 11 November 1980.
Smestad, et al. Injectable cross-linked collagen implant material. US 4,582,640, United States Patent and Trademark Office, 15 April 1986
Cohen S, Dover J, Monheit G, Narins R, Sadick N, Werschler WP, Karnik J, Smith SR. Five-Year Safety and Satisfaction Study of PMMA-Collagen in the Correction of Nasolabial Folds. Dermatol Surg. 2015 Dec;41 Suppl 1:S302-13. doi: 10.1097/DSS.0000000000000542.
Cohen SR, Holmes RE. Artecoll: a long-lasting injectable wrinkle filler material: Report of a controlled, randomized, multicenter clinical trial of 251 subjects. Plast Reconstr Surg. 2004 Sep 15;114(4):964-76; discussion 977-9. doi: 10.1097/01.prs.0000133169.16467.5f.
Related Links
Access external resources that provide additional context or updates about the study.
Zyderm® highly purified dermal collagen implant
BellaFill® Skin Test Instructions for Use (PN: 7252 Rev 00 (10/2018))
ArteFill® FDA Summary of Safety and Effectiveness (2006)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21-ASMI-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.